machine MD - Winner of the Ypsomed Innovation Award 2022

Press Releases Ypsomed Group

Burgdorf - The winners of the Ypsomed Innovation Award 2022 were honoured yesterday evening at the PwC Switzerland New Year's Apéro in Bern. The winners are machineMD (1st place), Pace Locator (2nd place) and Compact Motion (3rd place). The Innovation Award, worth a total of CHF 100,000, is presented every two years by the Ypsomed Innovation Fund Foundation. The aim is to promote the transfer of knowledge and technology from universities of applied sciences and universities in the "Espace Mittelland" region.

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) and Mediq are completing the sale of DiaExpert. The transaction strengthens Ypsomed's focus on the development, manufacture and distribution of its own high-quality medical technology products for people with chronic conditions.

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Eli Lilly and Company (NYSE: LLY) has decided to fully focus on its successful drug portfolio. Therefore, Lilly decided to stop the joint project with Ypsomed (SIX: YPSN) to enter the US insulin pump market in 2026. Ypsomed plans to submit its YpsoPump system to the FDA in the second half of 2023 according to plan, and subsequently commercialize the system with a new partner.

Press Releases Ypsomed Group

Burgdorf – Ypsomed announces that its mylife Loop is now authorized to work with Abbott’s FreeStyle Libre 3 sensor in Germany. The mylife YpsoPump and the FreeStyle Libre 3, combined with the mylife CamAPS FX algorithm from CamDiab, form an intelligent and automated insulin delivery system (AID) designed to help people with type 1 diabetes to better control their glucose levels and alleviate the burden of daily diabetes management.

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) is on track and achieved consolidated sales of CHF 244.2 million in the first half of the 2022/23 financial year (previous year: CHF 222.6 million). This corresponds to a growth of 9.7% compared with the previous year. At constant currency rates compared to the previous year, this would have represented an increase of around 13%. With this growth, the company has significantly increased its operating profit (EBIT) from CHF 10.5 million to CHF 19.4 million and doubled its net profits to CHF 15.4 million (previous year CHF 7.1 million). Despite a challenging general environment, Ypsomed confirms its positive assessment of future business development and its outlook.